Acute and one-year effects of cinacalcet in patients with persistent primary hyperparathyroidism after unsuccessful parathyroidectomy

American Journal of the Medical Sciences

Volumn 335, Issue 2, 2008, Pages 111-114

  Iglesias, Pedro ^a   Ais, Guillermo ^a   González, Ana ^a   Tajada, Pilar ^a   Arivalo, Carmen García ^a   Pardo, Enrique Fernández ^a   Díez, Juan J ^b  

^a HOSPITAL GENERAL DE SEGOVIA   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Cinacalcet; Parathyroidectomy; Primary hyperparathyroidism

Indexed keywords

ALENDRONIC ACID; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; BRONCHODILATING AGENT; CALCIUM; CINACALCET; ENALAPRIL; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PARATHYROID HORMONE; VERAPAMIL;

ADULT; AGED; ANAMNESIS; ARTICLE; CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CALCIUM URINE LEVEL; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG EFFECT; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABORATORY TEST; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PRIMARY HYPERPARATHYROIDISM; TREATMENT FAILURE; ULTRASOUND;

EID: 39149125785     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3181379f3e     Document Type: Article

References (11)

1. AACE/AAES Task Force on Primary Hyperparathyroidism: The American Association of Clinical Endocrinologists and the American Association of Endocrine Surgeons position statement on the diagnosis and management of primary hyperparathyroidism. Endocr Pract 2005;11:49-54.
2. Nemeth EF, Steffey ME, Hammerland LG, et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci U S A 1998;95:4040-5.
3. Kawata T, Imanishi Y, Kobayashi K, et al. Direct in vitro evidence of the suppressive effect of cinacalcet HCl on parathyroid hormone secretion in human parathyroid cells with pathologically reduced calcium-sensing receptor levels. J Bone Miner Metab 2006;24:300-6.
4. Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004;350:1516-25.
5. Lindberg JS, Culleton B, Wong G, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 2005;16:800-7.
6. Peacock M, Bilezikian JP, Klassen PS, et al. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2005;90:135-41.
7. Shoback DM, Bilezikian JP, Turner SA, et al. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 2003;88:5644-9.
8. Timmers HJ, Karperien M, Hamdy NA, et al. Normalization of serum calcium by cinacalcet in a patient with hypercalcaemia due to a de novo inactivating mutation of the calcium-sensing receptor. J Intern Med 2006;260:177-82.
9. Riccardi D, Hall AE, Chattopadhyay N, et al. Localization of the extracellular Ca2+/polyvalent cation-sensing protein in rat kidney. Am J Physiol 1998;274:F611-22.
10. Hedbäck G, Odén A. Persistent disease after surgery for primary hyperparathyroidism: the long-term outcome. Eur J Endocrinol 2004;150:19-25.
11. Bilezikian JP, Potts JTJ, Fuleihan GH, et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Bone Miner Res 2002;17(Suppl 2):N2-11.